LSKB is a privately-held biopharmaceutical company based in Salt Lake City, Utah. We are opening an office in the Bay Area. The Company specializes in the early clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two exciting drug candidates;
LSKB has scheduled an End-of-Phase 2 meeting with US FDA on July 20, 2016 to discuss clinical development plans for apatinib. The FDA guidance from this meeting will assist LSKB in finalizing the design of a pivotal Phase 3 study in patients with gastric cancer
LSKB is attending Bio International Convention June 6-9th in San Francisco at the Moscone Center - We are discussing product license and co-development opportunities. Schedule a meeting with us through the bio partnering system, or send us a message at alexkim@lskbiopharma.com.
LSKB is attending ASCO in Chicago at the McCormick Center June 2-7th. We will be meeting with key leading oncologists from across the globe to discuss late stage development of apatinib mesylate in gastric cancer, colorectal cancer, and hepatocellular carcinoma. Contact arlo.mcginn@lskbiopharma.com for more information.
LSKB is attending Bio Europe Spring in Stockholm - schedule a meeting with us through the partnering system, or send us a message at alexkim@lskbiopharma.com
LSK BioPharma (LSKB), which is currently developing two promising cancer drugs, announced that it has entered into a strategic alliance with the largest CRO in Korea, LSK Global PS. The strategic alliance will initially focus on the clinical development of apatinib, a drug which has
Salt Lake City– LSK BioPharma (LSKB) and the University of Utah’s Huntsman Cancer Institute (HCI) today announced an exclusive license agreement for LSKB to develop and commercialize HCI-1401, an orally bioavailable, small molecule, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). “BTK inhibitors are an exciting
Dr. Sunil Sharma and Dr. Yoon Koo Kang in front of the Apatinib poster at ASCO 2015. Read The Abstract
Salt Lake City, UT, June 6, 2012 - LSK BioPartners today announced the initiation of a Phase 1/2A dose escalation and safety trial of apatinib mesylate (YN968D1) with the enrollment of the first three patients of the first dose cohort. This is the first clinical
